tbuckley/cabot-search huggingface dataset:
Metabolic Cost of Exercise Initiation in Patients With Heart Failure With Preserved Ejection Fraction vs Community-Dwelling Adults
Authors: Ravi V. Shah, Mark W. Schoenike, Miguel Á. Armengol de la Hoz, Thomas F. Cunningham, Jasmine B. Blodgett, Melissa Tanguay, John A. Sbarbaro, Matthew Nayor, Jennifer Rouvina, Alyssa Kowal, Nicholas Houstis, Aaron L. Baggish, Jennifer E. Ho, Corey Hardin, Rajeev Malhotra, Martin G. Larson, Ramachandran S. Vasan, Gregory D. Lewis
Journal: JAMA Cardiology (2021)

Heart failure with preserved ejection fraction (HFpEF) is a joint metabolic and cardiovascular disorder with significant noncardiac contributions.To define and quantify the metabolic cost of initiating exercise in individuals with and without HFpEF and its functional consequences.This prospective cohort study included individuals with hemodynamically confirmed HFpEF from the Massachusetts General Hospital Exercise Study (MGH-ExS) and community-dwelling participants from the Framingham Heart Study (FHS). Analysis began April 2016 and ended November 2020.Internal work (IW), a measure of work equivalents required to initiate movement.Using breath-by-breath oxygen uptake (V̇o2) measurements and V̇o2-work rate associations, cost of initiating exercise (IW) in patients with HFpEF (MGH-ExS) and in community-dwelling individuals (FHS) was quantified. Linear regression was used to estimate associations between IW and clinical/hemodynamic measures.Of 3231 patients, 184 (5.7%) had HFpEF and were from MGH-ExS, and 3047 (94.3%) were community-dwelling individuals from FHS. In the MGH-ExS cohort, 86 (47%) were women, the median (interquartile range) age was 63 (53-72) years, and the median (interquartile range) peak V̇o2 level was 13.33 (11.77-15.62) mL/kg/min. In the FHS cohort, 1620 (53%) were women, the median (interquartile range) age was 54 (48-60) years, and the median (interquartile range) peak V̇o2 level was 22.2 (17.85-27.35) mL/kg/min. IW was higher in patients with HFpEF and accounted for 27% (interquartile range, 21%-39%) of the total work (IW + measured external workload on the cycle), compared with 15% (interquartile range, 12%-20%) of that in FHS participants. Body mass index accounted for greatest explained variance in patients with HFpEF from MGH-ExS and FHS participants (22% and 18%, respectively), while resting cardiac output and biventricular filling pressures were not significantly associated with variance in IW in patients with HFpEF. A higher IW in patients with HFpEF was associated with a greater increase in left- and right-sided cardiac filing pressure during unloaded exercise, despite similar resting hemodynamic measures across IW.This study found that internal work, a new body mass index-related measure reflecting the metabolic cost of initiating movement, is higher in individuals with HFpEF compared with middle-aged adults in the community and is associated with steep, early increases in cardiac filling pressures. These findings highlight the importance of quantifying heterogeneous responses to exercise initiation when evaluating functional intolerance in individuals at risk for or with HFpEF.
Mouse models of insulin resistance and IGF-1 deficiency in colon carcinogenesis
Authors: Kafi Ealey, Wanli Xuan, Suying Lu, Michael Archer
Journal: Cancer Research (2007)

2421  Insulin resistance is a risk factor for colon cancer, but it is not clear which of the metabolic consequences of insulin resistance are involved. Muscle-specific Insulin Receptor Knockout (MIRKO) mice exhibit elevated serum triglycerides (TG), free-fatty acids (FFA) and fat mass, but have normal body weight, circulating glucose and insulin and normal insulin sensitivity relative to their wild-type (WT) littermates. Liver-specific IGF-1 knockout (LID) mice have a significant reduction in circulating IGF-1 levels relative to their WT littermates. The objective of this study was to test in MIRKO mice the hypothesis that hyperlipidemia promotes colon cancer independent of changes in insulin, and in LID mice, that a reduction in IGF-1 protects against colon cancer. Seven-week old male MIRKO mice, 12-week old male and female LID mice and their WT littermates, were treated with AOM to induce aberrant crypt foci (ACF) or colon tumors. In MIRKO mice, ACF were assessed at 24 weeks of age and tumors at 40 weeks of age. Unexpectedly, the metabolic phenotype of the MIRKO mice changed significantly as the mice aged. Seven week-old MIRKO mice displayed hyperinsulinemia and at 16 weeks they displayed reduced insulin sensitivity. The previously reported MIRKO phenotype developed between 16 and 24 weeks of age. By 40 weeks of age, however, the serum metabolites as well as insulin were not different from WT, but the MIRKO mice were again insulin resistant. ACF development was not different in MIRKO and WT mice, but MIRKO mice had a reduced susceptibility to the development of tumors. Our results suggest that circulating TG and FFA are not promoters of colon carcinogenesis. Circulating adiponectin, however, was elevated in MIRKO mice by 24 weeks of age, suggesting that this adipokine may have inhibited formation of colon tumors. In LID mice, ACF were assessed at 16 and tumors at 40 weeks of age. Male and female LID mice had approximately 60% lower serum IGF-1 levels compared to WT littermates. Male LID mice were hyperinsulinemic relative to WT, though female LID mice had normal insulin levels. There was a significant inverse correlation between insulin and IGF-1 levels in males only, and there were no differences in total ACF between male LID and WT mice. Female LID mice, however, developed significantly fewer ACF compared to WT and there was a significant positive correlation between serum IGF-1 and total ACF. By 40 weeks of age, both male and female LID mice were hyperinsulinemic and there were no differences in tumor development compared to WT. There was a significant inverse correlation between insulin and IGF-1 in both males and females at this age suggesting that the reduced susceptibility to colon carcinogenesis caused by reductions in circulating IGF-1 may be masked by hyperinsulinemia. Taken together, these studies exclude circulating lipids as factors that increase risk of colon cancer development, but support the involvement of the insulin-IGF-1 axis.
Assessment of Psychotropic Drug Prescribing Among Nursing Home Residents in Ontario, Canada, During the COVID-19 Pandemic
Authors: Nathan M. Stall, Jonathan S. Zipursky, Jagadish Rangrej, Aaron Jones, Andrew P. Costa, Michael P. Hillmer, Kevin Brown
Journal: JAMA Internal Medicine (2021)

This cross-sectional study uses data from the Ontario Drug Benefit database to assess prescribing patterns of psychotropic drugs among nursing home residents in Ontario, Canada during the coronavirus disease 2019 pandemic.
P24.03 A Multicenter Randomized Phase III Trial of Dendritic Cell Maintenance Therapy After Chemotherapy in Mesothelioma; Denim Trial
Authors: R. Belderbos, P. Baas, R. Berardi, R. Cornelissen, D. Fennell, J. Meerbeeck, A. Scherpereel, H. Vroman, J. Aerts
Journal: Journal of Thoracic Oncology (2021)
CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma
Authors: Mary Chris Jaklevic
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Case Of Primary Pulmonary Diffuse Large B-Cell Lymphoma Initially Suspected Of Lung Abscess
Authors: J. Shim, K. Min, J. Sim, J. Choi, J. Oh, E. Lee, G. Hur, S. Lee, J. Kim, C. Shin, K. In, K. Kang
Journal: American Journal of Respiratory and Critical Care Medicine (2014)
P14.25 Immune Cell Profiling of Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Antibodies
Authors: K.H. Kim, J.Y. Hur, B.M. Ku, J. Koh, M. Ahn, E. Shin
Journal: Journal of Thoracic Oncology (2021)
MA06.11 The Collision of Good Syndrome and Autoimmunity in Thymic Epithelial Tumors
Authors: G. Palmieri, M. Giuliano, M. Tortora, P. Formisano, A. Marretta, V. D'Esposito, A.M. Malfitano, S. Parola, F. Picozzi, V. Riccio, S. Di Somma, P. De Placido, B. Mucci, E. Pietroluongo, M.A. Santomauro, B. Daniele, S. De Placido, M. Ottaviano
Journal: Journal of Thoracic Oncology (2021)
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Authors: Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine E. Kargus, Lynette M. Sholl, Junko Tsuji, David M. Hyman, Anne Sisk, Geoffrey I. Shapiro, Hebert A. Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski
Journal: Clinical Cancer Research (2021)

Abstract Purpose: This was a multicenter, histology-agnostic, single-arm prospective phase II trial of therapeutic activity of everolimus, an oral mTORC1 inhibitor, in patients with advanced solid tumors that harbored TSC1/TSC2 or MTOR mutations. Patients and Methods: Patients with tumors with inactivating TSC1/TSC2 or activating MTOR mutations identified in any Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory were eligible. Patients were treated with everolimus 10 mg once daily until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR). Whole-exome sequencing was performed to identify co-occurring genomic alterations. Results: Between November 2015 and October 2018, 30 patients were enrolled at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Tumors harbored TSC1 (13/30), TSC2 (15/30), concurrent TSC1 and TSC2 (1/30), or MTOR (1/30) mutations. The most common treatment-related adverse event of any grade was mucositis (8/30, 27%); 1 patient had fatal pneumonitis. Partial responses were seen in 2 patients [7%; 95% confidence interval (CI), 1%–22%]. Median progression-free survival was 2.3 months (95% CI, 1.8–3.7 months) and median overall survival (OS) was 7.3 months (95% CI, 4.5–12.7 months). There was no clear association between other genomic alterations and response. Of the 2 patients with objective response, 1 had upper tract urothelial carcinoma with biallelic inactivation of TSC1 and high tumor mutation burden, and the other had uterine carcinoma with biallelic TSC2-inactivating mutations and PEComa-like pathologic features. Conclusions: Everolimus therapy had a disappointing ORR (7%) in this pan-cancer, mutation-selected, basket study. See related commentary by Kato and Cohen, p. 3807
Looking Forward: A Response to Commentaries on “Race, Power and COVID-19: A Call for Advocacy within Bioethics”
Authors: Zamina Mithani, Jane Cooper, J. Wesley Boyd
Journal: The American Journal of Bioethics (2021)

Click to increase image sizeClick to decrease image sizeThis article refers to:Beyond the Medical Model: Retooling Bioethics for the Work AheadIt’s Time for a Black BioethicsRace-Conscious Bioethics: The Call to Reject Contemporary Scientific RacismAddressing Meso-Level Mechanisms of Racism in MedicineTrue Colors: Whiteness in BioethicsUpdating Race-Based Risk Assessment Algorithms in Clinical Practice: Time for a Systems ApproachBioethics as Engaged ActivityTransforming Bioethics: The Need for Strong Objectivity and StandpointsRace, Power, and COVID-19: A Call for Advocacy within BioethicsRace and Power at the Bedside: Counter Storytelling in Clinical Ethics ConsultationBeyond Seeing Race: Centering Racism and Acknowledging Agency Within Bioethics DISCLOSURE STATEMENTNo potential conflict of interest was reported by the author(s).
Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer
Authors: Maximilian Kießler, Ioana Plesca, Ulrich Sommer, Rebekka Wehner, Friederike Wilczkowski, Luise Müller, Antje Tunger, Xixi Lai, Anke Rentsch, Kenneth Peuker, Sebastian Zeissig, Adrian M Seifert, Lena Seifert, Jürgen Weitz, Michael Bachmann, Martin Bornhäuser, Daniela Aust, Gustavo Baretton, Marc Schmitz
Journal: Journal for ImmunoTherapy of Cancer (2021)

Plasmacytoid dendritic cells (pDCs) play a key role in the induction and maintenance of antitumor immunity. Conversely, they can act as tolerogenic DCs by inhibiting tumor-directed immune responses. Therefore, pDCs may profoundly influence tumor progression. To gain novel insights into the role of pDCs in colon cancer, we investigated the frequency and clinical relevance of pDCs in primary tumor tissues from patients with colon cancer with different clinicopathological characteristics.Immunohistochemical stainings were performed to explore the frequency of tumor-infiltrating BDCA-2+ pDCs in patients with colon cancer. Statistical analyses were conducted to determine an association between the pDC density and clinicopathological characteristics of the patients. Furthermore, we used multiplex immunofluorescence stainings to evaluate the localization and phenotype of pDCs in stroma and tertiary lymphoid structures (TLS) of colon cancer tissues.An increased density of infiltrating pDCs was associated with lower Union for International Cancer Control (UICC) stages. Furthermore, a higher pDC frequency was significantly correlated with increased progression-free and overall survival of patients with colon cancer. Moreover, a lower number of coloncancer-infiltrating pDCs was significantly and independently linked to worse prognosis. In addition, we found that a proportion of pDCs shows a nuclear expression of the transcription factor interferon regulatory factor 7 (IRF7), which is characteristic for an activated phenotype. In various tumor stroma regions, IRF7+ pDCs were located in the neighborhood of granzyme B-expressing CD8+ T cells. Moreover, pDCs were identified as a novel component of the T cell zone of colon cancer-associated TLS, which are major regulators of adaptive antitumor immunity. A proportion of TLS-associated pDCs displayed a nuclear IRF7 expression and was preferentially located close to CD4+ T cells.These results indicate that higher densities of tumor-infiltrating pDCs are associated with prolonged survival of patients with colon cancer. Moreover, colon cancer-infiltrating pDCs may represent a novel prognostic factor. The colocalization of activated pDCs and T cells in tumor stroma and within TLS may contribute to the correlation between higher pDC densities and better prognosis. In addition, our findings may have implications for the design of novel immunotherapeutic strategies that are based on targeting colon cancer-infiltrating pDCs.
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Authors: Martine Piccart, Laura J van 't Veer, Coralie Poncet, Josephine M N Lopes Cardozo, Suzette Delaloge, Jean-Yves Pierga, Peter Vuylsteke, Etienne Brain, Suzan Vrijaldenhoven, Peter A Neijenhuis, Sylvian Causeret, Tineke J Smilde, Giuseppe Viale, Annuska M Glas, Mauro Delorenzi, Christos Sotiriou, Isabel T Rubio, Sherko Kümmel, Gabriele Zoppoli, Alastair M Thompson, Erika Matos, Khalil Zaman, Florentine Hilbers, Debora Fumagalli, Peter Ravdin, Susan Knox, Konstantinos Tryfonidis, Aleksandra Peric, Bart Meulemans, Jan Bogaerts, Fatima Cardoso, Emiel J T Rutgers
Journal: The Lancet Oncology (2021)
Caregiver Perceptions of Adolescent Self-Management Skills Predicts Higher Disease Knowledge Among Adolescents with SCD
Authors: Anjelica C Saulsberry, Jason Hodges, Justin Williams, Megan Loew, Sheila Anderson, Audrey Cole, Guolian Kang, Chen Li, Robert Cronin, Jerlym Porter, Jane S Hankins
Journal: Blood (2017)
P76.100 Primary Drug Resistance to EGFR-TKIs by EGFR p.V1010M Germline Mutation Combined with EGFR p.L858R Somatic Mutation and its Pedigree Analysis
Authors: N. Li, C. Liu, L. Xiong, D. Huang, X. Shen, H. Zhang, X. She, Y. Jiang
Journal: Journal of Thoracic Oncology (2021)
Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial
Authors: Danbee Kang, Nayeon Kim, Young Hyuck Im, Yeon Hee Park, Ji Yeon Kim, Hyeokgon Park, Eunjoo Kim, Di Zhao, Eliseo Guallar, Jin Seok Ahn, Juhee Cho
Journal: Journal of the American Academy of Dermatology (2021)
R‐MACLO‐IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma ‐ Long term follow up results
Authors: Juan P. Alderuccio, Eduardo E. Saul, Sunil G. Iyer, Isildinha M. Reis, Alvaro J. Alencar, Joseph D. Rosenblatt, Izidore S. Lossos
Journal: American Journal of Hematology (2021)

We present long-term combined results of two clinical trials implementing R-MACLO-IVAM induction followed by thalidomide or rituximab maintenance in 44 patients with untreated mantle cell lymphoma (MCL). The first 22 patients (UM-MCL1 ClinicalTrials.gov identifier NCT00450801) received maintenance with thalidomide (200 mg daily until relapse/intolerable toxicity) and a subsequent cohort of 22 patients (UM-MCL2 ClinicalTrials.gov identifier NCT00878254) received rituximab (375 mg/m2 IV weekly × 4, repeated every 6 months for 3 years). Considering all 44 patients, 41 (93.2%) achieved complete response (CR), two (4.5%) partial response (PR), and one (2.3%) was not evaluated for response. With a median follow up of 7.2 years (range < 1 month to 16 years), the 5-year progression-free survival (PFS) was 55.6% (95% CI: 38.9%-69.4%) and median PFS 7.9 years (95% CI: 3.7-11 years). The 5-year OS was 83.3% (95% CI: 68.1%-91.7%) and median OS was not reached. Patients with blastic variant (n = 6) had a 5-year PFS and OS of 20.8% and 60%, respectively. Myelosuppression was the most common adverse event during immunochemotherapy. Long-term treatment-related mortality was 6.8%. Note, R-MACLO-IVAM followed by maintenance therapy is an effective regimen to induce long-term remission in MCL without need for consolidation with ASCT.
The Modified History of Tetralogy of Fallot During Childhood and Adolescence
Authors: Tamadhir F. Gazzaz, Bernadette Elders, Chun-Po Steve Fan, Cedric Manlhiot, Mike Seed, Shi-Joon Yoo, Glen van Arsdell, Lars Grosse-Wortmann
Journal: JACC. Cardiovascular imaging (2021)
P09.03 Thyroid Dysfunction in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors (ICI): Outcomes in a Multiethnic Urban Cohort
Authors: A. D'Aiello, J. Lin, R. Gucalp, V. Tabatabaie, H. Cheng, N. Bloomgarden, Y. Tomer, B. Halmos
Journal: Journal of Thoracic Oncology (2021)
MA13.02 Novel Non-Invasive Radiomic Signatures Extracted from Radiographic Images can Predict Response to Systemic Treatment in Small Cell Lung Cancer
Authors: P. Jain, M. Khorrami, A. Gupta, P. Rajiah, K. Bera, P. Vaidya, P. Fu, A. Dowlati, A. Madabhushi
Journal: Journal of Thoracic Oncology (2021)
Abstract 14160: Assessment of Atrial Fibrillation Burden by Smartwatch Photoplethysmography
Authors: Anthony Z Faranesh, Alexandros Pantelopoulos, Andreea Milescu, Conor Heneghan
Journal: Circulation (2019)

Introduction: Atrial fibrillation screening tools such portable ECG, blood pressure cuff, or smartphone photoplethysmography are single time-point measurements and are limited in detecting low to m...
FP03.01 Immune Microenvironment Features and Efficacy of PD-1/PD-L1 Blockade in Non-Small-Cell Lung Cancer Patients with EGFR or HER2 Exon 20 Insertions
Authors: K. Chen, Y. Xu, Z. Huang, X. Yu, Y. Fan
Journal: Journal of Thoracic Oncology (2021)
Lasting memories of SARS-CoV-2 infection
Authors: Maya M.L. Poon, Donna L. Farber
Journal: The Journal of Experimental Medicine (2021)

Maintaining virus-specific adaptive immunity is critical for ongoing protection against SARS-CoV-2 infection. In this issue, Breton et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20202515) identify polyfunctional SARS-CoV-2-specific T cell responses in the peripheral blood of individuals who recovered from COVID-19 that were present at 1 mo and persisted until 6 mo after infection.
P60.07 TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial
Authors: A. Cruz-Bermudez, M. Casarrubios, R. Laza Briviesca, E. Nadal, A. Insa, J. Mosquera, G. Huidobro, M. Dómine Gómez, B. Massuti, M. Majem Tarruella, D. Rodríguez-Abreu, A. Martinez-Marti, J. De Castro Campeño, M. Cobo Dols, G. López Vivanco, E. Del Barco, R. Bernabé Caro, N. Viñolas, I. Barneto, S. Viteri, M. Jove, A. Romero, F. Franco, M. Provencio
Journal: Journal of Thoracic Oncology (2021)
The Uncertain Role of Corticosteroids in the Treatment of COVID-19—Reply
Authors: Yuanlin Song, Chaomin Wu, Xiaoyan Chen
Journal: JAMA Internal Medicine (2020)

Chaomin Wu, MD; Xiaoyan Chen, MD; Yanping Cai, MD; Jia'an Xia, MD; Xing Zhou, MD; Sha Xu, MD; Hanping Huang, MD; Li Zhang, MD; Xia Zhou, MD; Chunling Du, MD; Yuye Zhang, BD; Juan Song, BD; Sijiao Wang, BD; Yencheng Chao, MD; Zeyong Yang, MD; Jie Xu, MD; Xin Zhou, MD; Dechang Chen, MD; Weining Xiong, MD; Lei Xu, MD; Feng Zhou, MD; Jinjun Jiang, MD; Chunxue Bai, MD; Junhua Zheng, MD; Yuanlin Song, MD
The microbiota is dispensable for the early stages of peripheral regulatory T cell induction within mesenteric lymph nodes
Authors: Carolin Wiechers, Mangge Zou, Eric Galvez, Michael Beckstette, Maria Ebel, Till Strowig, Jochen Huehn, Joern Pezoldt
Journal: Cellular and Molecular Immunology (2021)

Abstract Intestinal Foxp3 + regulatory T cell (Treg) subsets are crucial players in tolerance to microbiota-derived and food-borne antigens, and compelling evidence suggests that the intestinal microbiota modulates their generation, functional specialization, and maintenance. Selected bacterial species and microbiota-derived metabolites, such as short-chain fatty acids (SCFAs), have been reported to promote Treg homeostasis in the intestinal lamina propria. Furthermore, gut-draining mesenteric lymph nodes (mLNs) are particularly efficient sites for the generation of peripherally induced Tregs (pTregs). Despite this knowledge, the direct role of the microbiota and their metabolites in the early stages of pTreg induction within mLNs is not fully elucidated. Here, using an adoptive transfer-based pTreg induction system, we demonstrate that neither transfer of a dysbiotic microbiota nor dietary SCFA supplementation modulated the pTreg induction capacity of mLNs. Even mice housed under germ-free (GF) conditions displayed equivalent pTreg induction within mLNs. Further molecular characterization of these de novo induced pTregs from mLNs by dissection of their transcriptomes and accessible chromatin regions revealed that the microbiota indeed has a limited impact and does not contribute to the initialization of the Treg-specific epigenetic landscape. Overall, our data suggest that the microbiota is dispensable for the early stages of pTreg induction within mLNs.
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial
Authors: John H Stone, Jian Han, Martin Aringer, Daniel Blockmans, Elisabeth Brouwer, Maria C Cid, Bhaskar Dasgupta, Juergen Rech, Carlo Salvarani, Robert Spiera, Sebastian H Unizony, Min Bao
Journal: The Lancet Rheumatology (2021)